Lurie Children’s surpassed a hospital record in its recent fiscal year by performing a record 140 pediatric transplants, including, heart, kidney, liver and stem cell.
In a novel study that identified male chromosome genetic material in the intestines of female patients undergoing fecal transplants, researchers at Johns Hopkins Medicine say they have significantly expanded scientific understanding of how some of these transplants may succeed and work.
Ivan Maillard, MD, PhD, has been named Head of the Division of Hematologic Malignancies within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
SynCardia Systems, LLC., a Picard Medical Inc. company, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a second patent (US patent no. 12,121,711 B2) that will expand the coverage of SynCardia's fully implantable artificial heart technology (SynCardia Emperor). The USPTO allowed the first patent (US patent no. 11,918,797) relating to its groundbreaking "Next Generation Total Artificial Heart" designs in March of this year.
Findings from Rutgers Health and other researchers may lead to more precise treatment.
A new international trial is investigating the efficacy and safety of gene therapy in patients with Hurler syndrome and will compare results of gene therapy against BMT which is the current standard of care. UCSF Benioff Children’s Hospitals are among three sites in the U.S. and seven in the world now enrolling patients for the clinical trial.
Dr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.
Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.
IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
Investigators recently uncovered key insights into newly defined rejection entities in kidney transplantation that may offer improved patient risk categorization post-transplant. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Researchers from Johns Hopkins Children’s Center say they have identified a gene pathway involving the mineral zinc in mice that may someday point the way to using zinc-based supplements to directly help people with a rare disorder called short bowel syndrome (SBS).
Surgeons recently performed Mayo Clinic's first paired living liver donation, a significant first step in helping more people with liver failure get a lifesaving transplant.
In a world first, a pig kidney preserved at subzero temperatures was successfully transported across the Atlantic Ocean multiple times, demonstrating the potential for a novel technology to greatly extend organ storage and preservation, and make long-distance organ transportation a clinical reality.
Across the United States, around 100,000 organ donations are needed each year and an average of 28,000 transplants are performed across the country. Despite the ongoing need for donated organs for transplant, many donated organs end up being discarded for various reasons.
Nine new studies powered by the IRIS® Registry (Intelligent Research in Sight) will be presented this week at the 128th annual meeting of the American Academy of Ophthalmology.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
